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Abstract
Ozonide antimalarials, OZ277 (arterolane) and OZ439 (artefenomel), are synthetic perox-
ide-based antimalarials with potent activity against the deadliest malaria parasite, Plasmo-
dium falciparum. Here we used a “multi-omics” workflow, in combination with activity-based
protein profiling (ABPP), to demonstrate that peroxide antimalarials initially target the hae-
moglobin (Hb) digestion pathway to kill malaria parasites. Time-dependent metabolomic
profiling of ozonide-treated P. falciparum infected red blood cells revealed a rapid depletion
of short Hb-derived peptides followed by subsequent alterations in lipid and nucleotide
metabolism, while untargeted peptidomics showed accumulation of longer Hb-derived pep-
tides. Quantitative proteomics and ABPP assays demonstrated that Hb-digesting proteases
were increased in abundance and activity following treatment, respectively. Ozonide-
induced depletion of short Hb-derived peptides was less extensive in a drug-treated K13-
mutant artemisinin resistant parasite line (Cam3.IIR539T) than in the drug-treated isogenic
sensitive strain (Cam3.IIrev), further confirming the association between ozonide activity and
Hb catabolism. To demonstrate that compromised Hb catabolism may be a primary mecha-
nism involved in ozonide antimalarial activity, we showed that parasites forced to rely solely
on Hb digestion for amino acids became hypersensitive to short ozonide exposures. Quanti-
tative proteomics analysis also revealed parasite proteins involved in translation and the ubi-
quitin-proteasome system were enriched following drug treatment, suggestive of the
parasite engaging a stress response to mitigate ozonide-induced damage. Taken together,
these data point to a mechanism of action involving initial impairment of Hb catabolism, and
indicate that the parasite regulates protein turnover to manage ozonide-induced damage.
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Author summary
The ozonides are a novel class of fully synthetic antimalarial drugs with potent activity
against all parasite species that cause malaria, including the deadliest, Plasmodium falcipa-
rum. With the emergence of resistance to current frontline artemisinin-based antimalari-
als, new drugs are urgently needed and a clear understanding of their mechanism of
action is essential so that they can be optimally deployed in the field. Here, we studied the
biochemical effects of two ozonides, OZ277 (marketed in India in combination with
piperaquine) and OZ439 (in Phase IIb clinical trials) in P. falciparum parasites using an
untargeted multi-omics approach consisting of proteomics, peptidomics and time-depen-
dent metabolomics, along with activity-based protease profiling. We found that the ozon-
ides initially disrupt haemoglobin metabolism and that they likely engage the parasite
proteostatic stress response. Furthermore, when the duration of ozonide exposure was
extended beyond 3 hours to reflect clinically-relevant exposure periods, additional para-
site biochemical pathways were perturbed. This comprehensive analysis provides new
insight into the antimalarial mode of action of ozonides and provides new opportunities
for interventions to enhance their antimalarial efficacy.
Introduction
Promising improvements in malaria control have been recorded over the last two decades, but
recent data indicates that the declining mortality rates have either stalled or increased in many
malaria endemic regions since 2016 [1]. The absence of a reliable and highly efficacious vac-
cine means that treatment is heavily reliant on effective antimalarial chemotherapy. Currently,
the World Health Organisation (WHO) recommends artemisinin-based combination thera-
pies (ACTs) as the first-line treatment for uncomplicated Plasmodium falciparum malaria in
all endemic areas [2]. The artemisinins (including dihydroartemisinin, DHA) contain an
essential peroxide bond that undergoes reductive activation by haem released through parasite
haemoglobin (Hb) digestion [3–6]. This activation process generates highly reactive drug-
derived radicals that mediate rapid parasite killing [7]. However, artemisinins are limited by
poor biopharmaceutical properties and short in vivo half-lives (< 1 h) [7–9]. Furthermore, the
emergence of artemisinin resistant parasites now threatens global malaria control and elimina-
tion efforts [10]. Thus, there is a desperate need for improved therapeutics to combat malaria.
To overcome some of these limitations, the artemisinin peroxide bond inspired the design
of fully synthetic and structurally dissimilar peroxide-based antimalarials, known as ozonides
[11] (Fig 1). The first-generation ozonide, OZ277 (later known as RBx11160 or arterolane)
[11], was the first to be approved clinically, and although not currently recommended by
WHO, is currently marketed as a fixed dose combination with piperaquine (Synriam) in India
and parts of Africa. The in vivo half-life of OZ277 is only 2- to 3-fold longer than that for DHA
[12, 13]. This rapid clearance is thought to be associated with both hepatic metabolism [14]
and instability of the peroxide bond when exposed to endogenous sources of iron in blood and
tissues [15]. A design strategy aimed at stabilising the peroxide bond to iron-mediated degra-
dation led to the development and selection of the second-generation ozonide, OZ439 (artefe-
nomel) [15]. When tested clinically, OZ439 exhibited an in vivo half-life of 46–62 h in humans
[16, 17]. OZ439 is currently in Phase IIb clinical trials in combination with ferroquine (Clini-
calTrials.gov Identifier: NCT02497612).
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Ozonide antimalarials display similar clinical efficacy to DHA, rapidly clearing blood-stage
parasites [17, 18]. However, their antimalarial mechanism of action (MoA) has been less exten-
sively studied than the artemisinins, and debate remains about the key molecular events
responsible for artemisinin action [19–24]. The current model for ozonide antimalarial activity
is that Hb-derived free haem mediates reductive activation of the peroxide bond giving rise to
toxic carbon-centred radicals [25] that alkylate a number of essential parasite proteins from
various biochemical pathways [26, 27]. Crucially, optimal clinical utilisation of ozonides will
rely on a clear understanding of the biochemical mechanisms that underpin their activity.
Therefore, we investigated the temporal biochemical response of P. falciparum parasites
treated with OZ277 and OZ439 using systems-wide analyses, incorporating time-dependent
metabolomics and proteomics. We identified Hb digestion as the key initial pathway targeted
by ozonide antimalarials and demonstrated that when parasites are forced to rely solely on Hb
digestion for nutrients, they become hypersensitive to pulsed ozonide treatment. Furthermore,
we showed that ozonides perturb additional pathways when treatment was extended beyond 3
h, reflecting more clinically-relevant exposures for the ozonides, and that parasites likely regu-
late protein turnover to manage ozonide-mediated damage. This work provides new opportu-
nities for interventions to target malaria parasites and enhance ozonide antimalarial efficacy.
Results
Ozonide antimalarials initially deplete short haemoglobin (Hb)-derived
peptides
In order to distinguish the early peroxide-induced effects from secondary mechanisms, we
employed a time-dependent, untargeted metabolomics approach that allowed comprehensive
biochemical profiling of the primary pathways affected by ozonide antimalarials in P. falcipa-
rum infected red blood cells (iRBCs) (S1 Fig). Trophozoite-stage parasites (28–34 h post inva-
sion) were treated with 300 nM of OZ277 or OZ439 or 100 nM of DHA over a time course of
up to 3 h (n = at least four biological replicates). These drug concentrations are equivalent to
the IC50 for a 3 h pulse, under the same in vitro conditions used in the metabolomics analysis
(10% parasitaemia and 2% Hct) [28], and are within therapeutic concentration ranges [10,
17, 29]. Univariate analysis of the untargeted metabolomics dataset (S1 Dataset) revealed a
temporal increase in the percentage of drug-induced metabolic changes (S2A Fig) and that
Fig 1. Chemical structures of selected peroxide antimalarials. The fully synthetic ozonide antimalarials, OZ277
(arterolane) and OZ439 (artefenomel), and the clinically used semisynthetic artemisinin derivative,
dihydroartemisinin (DHA).
https://doi.org/10.1371/journal.ppat.1008485.g001
PLOS PATHOGENS Multi-omics analysis of ozonide mode of action
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008485 June 26, 2020 3 / 32
widespread metabolic perturbations were not evident after short drug exposures (S2B Fig).
The ozonides rapidly and disproportionately affected peptide metabolism, with approximately
15–25% of all putatively identified short peptides (2–4 amino acids in length) significantly per-
turbed within 3 h of drug treatment (P-value < 0.05) (S2B Fig). These significantly perturbed
peptides were parasite-specific metabolites (S1 Dataset) and exhibited a progressive depletion
in abundance over the 3 h drug exposure (Fig 2A and 2B). Interestingly, the extent of peptide
depletion was more extensive and faster in DHA-treated parasites compared to the ozonides,
which is consistent with the more rapid kinetics of antiparasitic activity previously observed
for DHA compared to the ozonides for these short pulse exposures (< 3 h) [30]. The amino
acid sequence of a subset of these putatively identified peptides was confirmed by MS/MS and
the majority of perturbed peptides (i.e., those that were decreased by at least 1.5-fold) could be
mapped to either the alpha or beta chains of Hb (Fig 3A).
A similar, although less extensive, temporal increase in the number of significant metabolic
perturbations was confirmed in ring-stage parasites (6–12 h post invasion) treated with ozon-
ide antimalarials (S3A Fig), with putative Hb-derived peptides representing the first metabo-
lites to be significantly perturbed (S1 Dataset and S3B Fig). This was further verified using
multivariate analysis, where sparse partial least squares–discriminant analysis (sPLS-DA)
revealed that Hb-derived short peptides were responsible for the greatest differences between
the ozonide-treated samples and controls (S4 Fig). Similar to trophozoite-stage parasites, these
Hb peptides showed a time-dependent depletion in the treated parasite cultures compared to
controls (Fig 3C).
To further investigate the importance of parasite Hb digestion to ozonide antimalarial
action, untargeted metabolomic profiling was also performed on artemisinin resistant (Cam3.
IIR539T) and isogenic sensitive (Cam3.IIrev) [31] early trophozoite-stage (22–26 h post inva-
sion) parasites (S2 Dataset). Artemisinin resistant early trophozoite-stage parasites have been
shown to exhibit differential sensitivity to short DHA exposures compared to the isogenic sen-
sitive strain, albeit a less dramatic difference than early rings [32]. Targeted analysis of the
LC-MS raw data identified 26 perturbed peptides (at least 1.5-fold) in drug-treated resistant
(Cam3.IIR539T) or sensitive parasites compared to control (Fig 2D). The majority (> 70%) of
perturbed peptides were depleted in treated samples compared to the control (Fig 2D and S5A
Fig) and most of these peptides (all except two) could be mapped to Hb (S5B Fig). Notably, the
extent of peptide depletion was greater in the sensitive parasites than in the resistant line (Fig
2D). In general, the abundance of these peptides in treated resistant parasites remained at, or
above, the basal levels detected in untreated sensitive parasites.
Ozonide antimalarial treatment causes accumulation of long chain Hb
peptides
The rapid depletion of short chain Hb-derived peptides led us to consider how ozonide anti-
malarial exposure impacts longer Hb-derived peptides. We used a MS/MS-based global pepti-
domics approach (S1 Fig) to examine the abundance of endogenous peptides (< 10 kDa)
within ozonide-treated P. falciparum parasites. Peptidomics analysis identified a total of 59
endogenous P. falciparum peptides and 59 endogenous human peptides (S3 Dataset). OZ277
(300 nM for 3 h) treatment significantly altered the abundance of 30 endogenous peptides in
trophozoites-stage parasites (P-value < 0.05), 17 of which originated from Hb (alpha and
beta), and were increased in abundance (Fig 3B). A similar build-up of long chain Hb peptides
was also observed following treatment with OZ439 (300 nM for 3 h). Unlike the ozonides,
exposure of trophozoite-stage parasites to 3 h of DHA (100 nM) predominantly depleted the
abundance of Hb-derived peptides, with 26 peptides significantly depleted and four
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significantly elevated relative to control (Fig 3B). The differential impact of ozonides and DHA
on longer chain Hb-derived peptides may be explained by the faster onset of action of artemi-
sinins compared to ozonides [30]. Indeed, a shorter DHA exposure (1 h) caused an accumula-
tion of longer Hb peptides similar to the ozonides (Fig 3C and S4 Dataset).
We also assessed whether the accumulated Hb components in peroxide-treated parasites
differ from those in E64d (cysteine protease inhibitor)-treated parasites. E64d causes parasite
digestive vacuoles to accumulate undegraded Hb and swell due to disruption of the initial
endoproteolytic cleavage of Hb [33, 34]. Trophozoite-stage parasites treated with E64d for up
to 3 h developed a characteristic swollen digestive vacuole (S6A Fig), consistent with abrogated
digestion of full-length Hb. These same parasites exhibited a modest trend towards accumula-
tion of intact Hb and minor changes in free haem and haemozoin levels (S6A Fig) when these
haem-containing species were measured using haem fractionation assays [35]. Visualisation of
monomer Hb (17 kDa) by Coomassie staining of SDS-PAGE gels confirmed that undigested
Hb accumulated in trophozoites after these short E64d exposures (S6B Fig). Conversely, per-
oxide-treated parasites showed a minor decrease in the levels of full-length Hb, when mea-
sured using the haem fractionation assay (no changes in other haem species were evident)
(S6A Fig), which is broadly consistent with our quantitative proteomics data (S6C Fig). Perox-
ide exposures of up to 3 h caused no changes in digestive vacuole morphology, indicating that
there is no inhibition of proteolysis of full-length Hb (S6A Fig). Taken together, these findings
suggest that the accumulated Hb components in peroxide-treated parasites are likely different
from those resulting from specific inhibition of cysteine proteases.
Our untargeted peptidomics analysis also showed that ozonide treatment perturbed the lev-
els of some endogenous parasite peptides. Of the 13 parasite peptides significantly perturbed
following OZ277 exposure, five originated from an uncharacterised P. falciparum protein
(PF3D7_0716300) and were decreased in abundance compared to control (S3 Dataset). OZ439
treatment resulted in significant perturbations to five parasite peptides, four of which were
from this same uncharacterised protein (PF3D7_0716300) and were decreased relative to the
untreated (S3 Dataset). A total of 15 endogenous parasite peptides were altered in abundance
following DHA treatment, including six peptides that originated from the uncharacterised
protein PF3D7_0716300 and, similar to ozonide exposure, were significantly decreased com-
pared to control (S3 Dataset).
Ozonide antimalarial treatment increases the abundance and activity of Hb
proteases
Plasmodium parasites digest Hb through a semi-ordered proteolytic process incorporating
numerous proteases of different classes [36]. Peptidomics and metabolomics analyses of
treated parasites suggested that ozonide antimalarials disrupt Hb catabolism through inhibi-
tion of the proteases involved in the breakdown of large to small Hb peptides. In order to
quantify the abundance of the proteases involved in Hb digestion, we used dimethyl labelling-
Fig 2. Peroxide-induced perturbations to peptide metabolism. a, Heatmap showing the average fold change for all identified peptides at each time point after treatment
of trophozoite-infected cultures (P. falciparum 3D7 strain) with OZ277, OZ439 and DHA. Values represent the average of at least three biological replicates, expressed
relative to the average untreated control value (at least seven biological replicates) for that respective time point. Putative haemoglobin peptides are shown in red text. b,
Representative time profiles showing the progressive depletion in abundance of selected putative haemoglobin-derived peptides after peroxide treatment of trophozoite-
stage parasites (3D7). Values are the average fold change (± SD) relative to the untreated control of at least three biological replicates. c, Time-dependent decrease in the
abundance of the four haemoglobin-derived peptides consistently depleted following peroxide treatment in ring infected cultures (3D7). Values are the average fold
change (± SD) relative to the untreated control of four biological replicates. d, Heatmap of the peptides that were altered in abundance (� 1.5-fold relative to the untreated
control) following peroxide treatment in the K13-wildtype artemisinin sensitive (Cam3.IIrev) and K13-mutant artemisinin resistant (Cam3.IIR539T) parasite lines. Data
shown are the average for three or five biological replicates expressed relative to the average for the untreated control from the same parasite line. Putative haemoglobin
peptides are shown in red text.
https://doi.org/10.1371/journal.ppat.1008485.g002
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based quantitative proteomics (S1 Fig) [37]. Targeted analysis of the global proteomics data
(S7 Fig and S5 Dataset) identified falcipains 2 and 3 (FP 2 and FP 3) and the plasmepsins (PM
I, PM II, PM IV and HAP), proteases thought to be involved in the initial stages of Hb degra-
dation [36], to be elevated in abundance in drug-treated samples compared to control (Fig
4A). Dipeptidyl aminopeptidase 1 (DPAP1), which removes dipeptides from the polypeptides
produced by upstream proteases [38], and the alanyl aminopeptidase (PfA-M1), leucyl
Fig 3. Sequence coverage and relative abundance of haemoglobin alpha (Hb α) and haemoglobin beta (Hb β) peptides detected after peroxide treatment. a,
Sequence coverage for putative haemoglobin-derived di-, tri-, and tetra-peptides that were differentially abundant (� 1.5-fold) following peroxide antimalarial treatment
relative to the untreated control (3D7 parasites). The peptide sequences PA, PT, PE, PEE, HLD, SLD, PPVQ, PVNF and HVDD have been confirmed by MS/MS analysis.
For all other putative peptide sequences, all potential isomers have been mapped. b, Sequence coverage for all long Hb α and Hb β peptides detected in peptidomics
studies. Peptide abundances are the average fold change following 3 hours of drug treatment (OZ277, OZ439 and DHA), expressed relative to the untreated control
(DMSO) from at least three biological replicates (3D7 parasites). c, Sequence coverage for Hb α and Hb β peptides detected following 1 hour of DHA treatment in Cam3.
IIrev (artemisinin sensitive) parasites. Peptide abundances are the average fold change expressed relative to the untreated control (DMSO) from two biological replicates. In
b, c, samples were normalised according to peptide concentration (measured using a bicinchoninic acid assay) during sample preparation. The solid lines represent the
amino acid sequences of peptides that significantly changed in abundance after drug treatment relative to the untreated control (P-value< 0.05). Dashed lines represent
non-significant (NS) changes. Increased and decreased peptide abundance are represented by red and blue (solid or dashed) lines, respectively.
https://doi.org/10.1371/journal.ppat.1008485.g003
PLOS PATHOGENS Multi-omics analysis of ozonide mode of action
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008485 June 26, 2020 7 / 32
Fig 4. Peroxide antimalarials act by perturbing haemoglobin digestion. a, Disruption of protease abundance in the haemoglobin digestion pathway [36]. Values are the
average log2 fold change (± SD) relative to the untreated control of at least three biological replicates. Trophozoite infected cultures (P. falciparum 3D7) were incubated
with OZ277, OZ439 (both 300 nM) or DHA (100 nM) for 3 h. Falcipain 2 (FP 2) was identified in only two OZ277 treatment experiments, therefore the mean alone is
shown. Aminopeptidase P (PfAPP) was not identified in any of the proteomic experiments. DPAP1, dipeptidyl aminopeptidase 1; FP, falcipain; HAP, histo-aspartic
protease; PfAPP, aminopeptidase P; PfA-M1, alanyl aminopeptidase; PfA-M17, leucyl aminopeptidase; PfM18APP, aspartyl aminopeptidase; PM, plasmepsin; � P-
value< 0.05. b, Parasite cysteine protease activity after peroxide treatment using the activity-based probe (ABP), DCG04. Cysteine protease activity and densitometric
analysis of the falcipain (FP) 2/3 and dipeptidyl aminopeptidase 1 (DPAP1) signal after OZ277 and OZ439 treatment in P. falciparum trophozoite stage parasites (3D7)
using DCG04 in lysates at pH 5.5 (acidic). Trophozoite infected cultures were incubated with OZ277, OZ439 (both 300 nM) or an equivalent volume of DMSO (control).
DCG04 labelling was detected by blotting membranes with streptavidin-AF647 after SDS-PAGE and transfer. The lanes for each time point are independent drug
treatments and represent at least three biological replicates per time point that were run on the same gel side-by-side. For the densitometric analysis, the post drug
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aminopeptidase (PfA-M17) and aspartyl aminopeptidase (PfM18AAP) metalloproteases, all of
which are involved in the terminal stages of Hb digestion [39], were all increased following
ozonide treatment (Fig 4A). No changes in the abundance of falcilysin (Fig 4A) was detected
(S5 Dataset).
As most Hb-degrading proteases were elevated in abundance after ozonide antimalarial
treatment, we then investigated the temporal impact of ozonides on Hb protease activity using
activity-based probes (ABPs) targeting parasite cysteine proteases [40] (S1 Fig). Trophozoite-
stage parasite cultures were treated with OZ277 or OZ439 (300 nM) for up to 5 h and the bioti-
nylated epoxide ABP, DCG04 [41], was used to label the Hb-digesting cysteine proteases FP 2,
FP 3 and DPAP1 in the parasite lysate under both acidic (pH 5.5) and neutral pH (pH 7.2) con-
ditions. Both OZ277 and OZ439 caused a time-dependent increase in the activity of proteases
with molecular weights consistent with that of the FPs (FP 2 and FP 3), and DPAP1 [42] (Fig
4B). A similar increase in the activity of these proteases was observed under acidic (the pH
environment of the parasite digestive vacuole) or neutral pH conditions (S8A Fig), and activity
was inhibited by pre-treatment of the parasite lysate with the cysteine protease inhibitor,
ALLN (S8B Fig). FPs and DPAP1 activity were increased within 1 h of OZ277 treatment com-
pared with DMSO controls (Fig 4B). In contrast, OZ439 increased FPs and DPAP1 activity
after 3–5 h of drug exposure, consistent with it having a slower onset of action within the para-
site [30]. Ozonide-induced increases in activity of FPs and DPAP1 were further confirmed by
another cysteine protease-targeting probe, FY01 [42], under both acidic (S9A Fig) and neutral
(S9B Fig) conditions. While total protein levels between the treatment and control groups
were normalised prior to incubation with the ABP, it is likely that increased FP and DPAP
abundance in response to peroxide treatment (as determined by quantitative proteomics; Fig
4A) is a major contributing factor to the increase in protease activity observed in these
experiments.
Impaired Hb digestion underpins initial ozonide-induced toxicity
Functional Hb uptake and digestion is essential for parasite survival as it supplies amino acids
for protein synthesis [43]. As our multi-omics and ABPP analyses identified Hb catabolism as
the primary pathway affected by ozonide antimalarial treatment, we hypothesised that drug-
derived radicals initially target this pathway, disrupting Hb catabolism, and starving the para-
site of Hb-derived amino acids. To test this, we determined the potency of peroxide antimalar-
ials on parasites grown in full RPMI medium (with all 20 amino acids) (AA medium) and
parasites cultured in medium lacking all exogenous amino acids except for isoleucine (the only
amino acid absent from Hb) (Iso medium), thereby forcing parasites to rely solely on Hb
catabolism for amino acid supply (Fig 4C).
Similar to published results [43], parasites cultured in Iso medium had a minor growth
defect of approximately 20% compared to parasites cultured in AA medium (Fig 4D). Tropho-
zoite-stage cultures exposed to OZ277 or OZ439 (both 300 nM) for 3 h were sensitised by 2.3-
and 1.6-fold, respectively, in the Iso medium (Fig 4E), suggesting that compromised Hb
treatment FP 2/3 and DPAP1 signal intensity was normalised to the average signal intensity of the appropriate time point in the untreated control (±SD). c, Schematic
showing that infected RBCs treated with DHA or ozonides (OZ) can use exogenous amino acids when cultured in AA medium (Full RPMI medium with all 20 amino
acids) in response to disrupted haemoglobin digestion (arrow shown in blue), while parasites in Iso medium (supplemented with isoleucine alone at a final concentration
of 147.5 μM) must rely solely on haemoglobin digestion for amino acids. d, Amino acid requirement for cultured P. falciparum 3D7 parasites. Parasite viability measured
following 48 h incubation in medium containing all amino acids (AA, black bars) and isoleucine alone medium (Iso, grey bars). e, Parasite sensitivity to peroxides when
cultured in AA (black bars) medium compared to Iso (grey bars) medium. Trophozoite infected cultures (3D7) were incubated with pyrimethamine (PYR), OZ277,
OZ439 (all 300 nM), DHA (100 nM) or an equivalent volume of DMSO (control) for 3 h. Data represents the mean ± SD of at least three biological replicates. Growth
values for each treatment is expressed relative to the appropriate untreated medium (Iso or AA) control, which was set to 100%. � P-value< 0.05.
https://doi.org/10.1371/journal.ppat.1008485.g004
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catabolism is the primary MoA of ozonides in the initial exposure phase. However, when drug
pressure was maintained throughout the entire RBC life cycle, there was no difference in sensi-
tivity between parasites cultured in the Iso and AA mediums (S10 Fig), suggesting that mecha-
nisms beyond disrupted Hb digestion contribute to parasiticidal activity during prolonged
exposure. DHA treated parasites were almost 5-fold more sensitive in the Iso medium com-
pared to parasites cultured in AA medium (Fig 4E). In contrast, the potency of pyrimethamine,
which kills parasites by a mechanism independent of Hb digestion [44], was not affected when
cultured in either AA or Iso medium (Fig 4E).
Ozonide antimalarial treatment upregulates parasite proteasome and
translation machinery proteins
Untargeted analysis of our global quantitative proteomics dataset (S5 Dataset) identified a total
of 1293, 1284 and 1613 proteins (including human and P. falciparum proteins) with at least
two unique peptides in a minimum of three independent biological experiments in OZ277,
OZ439 (both 300 nM) and DHA (100 nM) treated parasites, respectively. Peroxide treatment
caused significant dysregulation (P-value� 0.05 and fold-change� 1.5) to a subset of proteins
within 3 h of drug exposure (S7 Fig). Perturbation of the parasite proteome was most dramatic
after DHA treatment, with 12% of the 1552 P. falciparum proteins detected being significantly
increased in abundance and 6% significantly downregulated compared to the untreated level.
Of the 1255 P. falciparum proteins detected after OZ277 treatment, 7% were increased in
abundance and 1.6% were decreased compared to the control. OZ439 had the least pro-
nounced impact on the parasite proteome (1243 P. falciparum proteins detected), with 1.6%
and< 1% of proteins significantly increased and decreased relative to control levels,
respectively.
Clustering analysis of all proteins significantly perturbed (P-value� 0.05 and fold-
change� 1.5) by OZ277 treatment revealed that translation regulation (P-value = 5.184E-7)
and the proteasome system (P-value = 5.288E-4) were the two main pathways affected. Parasite
proteins in these two networks were significantly enriched following OZ277 treatment (Fig 5).
Similar protein clustering was also observed for DHA (S11 Fig) treatment, with elevated levels
of proteins involved in translation regulation (P-value < 1.0E-9) and the proteasome system
(P-value 3.691E-6). A trend towards increased abundance of translation regulation and protea-
some system proteins was also observed following 3 h of OZ439 exposure (S5 Dataset), how-
ever no protein networks were significantly enriched.
Extended exposure disrupts secondary metabolic pathways involved in
ozonide antimalarial activity
Using untargeted metabolomic profiling, we also investigated whether parasite biochemical
pathways other than Hb metabolism were affected following long-term ozonide treatment
(> 3 h). Extended exposure induced metabolic perturbations beyond peptide metabolism,
including, amino acid, lipid, cofactor and vitamin, and nucleotide metabolism (Fig 6A and S1
Dataset). It is possible that some of these secondary responses to prolonged drug treatment
represent nonspecific responses from dying parasites, but it is noted that different drug-spe-
cific responses were reported in similar metabolomics studies of other compounds [45–47],
suggesting that these metabolic alterations are largely ozonide-specific. Extended treatment of
trophozoite-stage parasites with OZ277 and OZ439 resulted in significant perturbations (P-
value� 0.05 and fold-change� 1.5) to approximately 5% of the 217 putatively identified lipids
(S12 Fig). The major parasite neutral glycerolipid species, diglycerides (DG) and triglycerides
(TG), were depleted within 6 h of ozonide exposure (S12 Fig). DGs are the direct metabolic
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precursor of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids, the main
glycerophospholipids in the parasite. Metabolites involved in PC and PE de novo synthesis
accumulated in a time-dependent manner following extended ozonide treatment, while some
of the PCs and PEs themselves, and other glycerophospholipids, were depleted (Fig 6B and S12
Fig). At the proteome level, four of the six enzymes in the de novo glycerophospholipid synthe-
sis pathway (Kennedy pathway) were elevated after ozonide treatment compared to control
(Fig 6B and S13 Fig). Prolonged treatment of rings (> 3 h) also disrupted de novo synthesis of
PC and PE lipids (S14 Fig).
Extended ozonide exposure also disrupted parasite pyrimidine nucleotide biosynthesis.
Metabolites of the de novo pyrimidine biosynthesis pathway, L-aspartate, N-carbamoyl-L-
aspartate and uridine monophosphate (UMP), were all depleted after drug treatment (Fig 6C
and S15 Fig), while at the proteome level, four of the six enzymes in this pathway were elevated
compared to the control (Fig 6C and S16 Fig).
Fig 5. OZ277-induced disruption to the P. falciparum (3D7 strain) proteome. Network analysis of trophozoite stage parasite proteins perturbed following treatment
with OZ277 (300 nM for 3 h). The network analysis was built using the STRINGdb interaction network analysis output (connectivity was based on experimental, database
and co-expression evidence with a minimum interaction score of 0.7) in Cytoscape 3.6 with the ClusterONE algorithm. Node size represents P-value and node colour
represents fold-change from at least three independent replicates.
https://doi.org/10.1371/journal.ppat.1008485.g005
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Discussion
This study provides a detailed assessment of the P. falciparum biochemical pathways that are
altered in response to ozonide antimalarial treatment. The “multi-omics” analysis revealed
that ozonides act by rapidly perturbing parasite Hb catabolism prior to affecting other bio-
chemical pathways, and suggested that the parasite regulates protein turnover to mitigate
widespread ozonide-induced damage.
The time-resolved untargeted metabolomics approach allowed the mapping of primary and
secondary ozonide-induced effects on parasite metabolism and revealed that short drug expo-
sures induced rapid depletion of short-chain Hb-derived peptides, which was most pro-
nounced in the more susceptible trophozoite-stage, in comparison to the less susceptible [28,
30] ring-stage parasites (Fig 2 and S3 Fig). It is noted that previous metabolomic profiling of
ozonide-treated, magnetically purified P. falciparum cultures revealed no major alterations to
parasite metabolism [47]. However, that was likely due to the high parasitaemia conditions
(> 90%) of magnetically purified cultures inducing rapid ozonide degradation such that no
measurable antimalarial activity could occur [28]. Consistent with previous reports [45, 46],
our metabolomics analysis also showed that DHA induced depletion of short Hb-derived pep-
tides. Interestingly, this occurred more rapidly for DHA than the ozonides (within 1.5 h of
exposure versus 3 h of exposure), which agrees with the reported exposure time-dependence
of activity for DHA and ozonides [30].
Digestion of host Hb is essential for parasite survival as it provides amino acids for parasite
protein synthesis and has additional non-anabolic functions, such as maintaining osmotic sta-
bility of the iRBC [48–50]. Hb digestion is most active during the trophozoite-stage [51],
resulting in extensive turnover of diverse Hb-derived peptides and the release of a high con-
centration of haem, which activates peroxide antimalarials within the parasite [3, 30, 52]. The
extensive drug activation and Hb turnover in trophozoites likely explains the profound impact
of peroxide antimalarials on Hb-derived small peptides in trophozoites (in terms of both the
range of Hb peptides affected and magnitude of peptide depletion) compared to the ring-stage
(Fig 2). Although it is generally assumed that little Hb digestion occurs within ring-stage para-
sites, expression of active Hb-degrading proteases [30] and small haemozoin crystals (by-prod-
ucts of Hb digestion) have been detected [53–55]. This indicates that a low level of active Hb
degradation occurs in ring-stage parasites and supports the observation of depleted Hb-
derived small peptides following ozonide treatment (Fig 2C and S3 and S4 Figs).
The accumulation of longer Hb-derived peptides (Fig 3B) and depletion of shorter di, tri
and tetrapeptides (Fig 2) suggests that the ozonides disrupt Hb catabolism through an inhibi-
tory effect on the proteases involved in the conversion of large to small Hb peptides. However,
we cannot rule out inhibition of the peptide transporters on the digestive vacuole membrane,
or general impairment of digestive vacuole function, as contributors to this peptide phenotype.
Fig 6. Peroxide-induced disruption of secondary biochemical pathways. a, Metabolic perturbations in trophozoite-stage parasite cultures (P. falciparum
3D7 strain). Pathway enrichment analysis showing the percentage of significantly perturbed metabolites (Welch’s t test; P-value< 0.05 and fold
change> 1.5) as a function of metabolite class for extended (3, 6 and 9 h) exposure with OZ277, OZ439 (both 300 nM) and DHA (100 nM). b, Peroxide-
induced disruption of the phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipid biosynthesis pathways within P. falciparum parasites (3D7).
The dashed arrows represent an alternative route for the synthesis of PC from ethanolamine (Etn) in P. falciparum. CCT, choline-phosphate
cytidyltransferase; CDP-, cytidine-diphospho-; CEPT, choline/ethanolamine phosphotransferase; Cho, choline; CK, choline kinase; CMP, cytidine
monophosphate; DAG/DG, diglyceride; DM-, dimethyl-; ECT, ethanolamine-phosphate cytidyltransferase; EK, ethanolamine kinase; Etn, ethanolamine;
MM-, monomethyl; PC, phosphatidylcholine; PCho, choline phosphate; PE, phosphatidylethanolamine; PEtn, ethanolamine phosphate; PG,
phosphatidylglycerol; PMT, phosphoethanolamine N-methyltransferase; PS, phosphatidylserine; PSD, phosphatidylserine decarboxylase; PSS,
phosphatidylserine synthase; SD, serine decarboxylase. c, Peroxide-induced perturbation of pyrimidine biosynthesis in trophozoite-stage parasite cultures
(3D7). Hb, haemoglobin; UMP, uridine monophosphate. In b, c, metabolites (circles) and proteins (squares) in red and blue were increased and decreased
in abundance after drug treatment, respectively. Yellow and black represent no change and not detected, respectively.
https://doi.org/10.1371/journal.ppat.1008485.g006
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In response to perturbations within the digestive vacuole and impaired Hb catabolism, we pro-
pose that the parasite engages an ultimately futile compensatory mechanism that increases the
abundance and activity of all proteases involved in Hb digestion, except falcilysin (Fig 4A). Fal-
cilysin has been shown to localise to both the parasite apicoplast and the digestive vacuole, sug-
gesting that it may have a function beyond Hb catabolism [56, 57]. The activity of cysteine
proteases involved in Hb digestion was elevated within 1 h of ozonide exposure, before the
first time point of significant small peptide depletion (1.5 h), indicating that increasing Hb
protease capacity may allow the parasite to successfully compensate for disrupted Hb digestion
for a short period. Alternatively, the rapid peroxide effect on Hb catabolism may occur before
there is a detectable change in small peptide levels using metabolomics.
Rapid disruption of Hb catabolism by the ozonides (and artemisinins) agrees with the
hypothesis that peroxide-based drugs are activated by Fe(II) or haem to produce reactive inter-
mediates in the parasite digestive vacuole where Hb digestion takes place. The resulting ozon-
ide-derived radicals were recently shown to alkylate haem within iRBCs after short drug
exposures [58] and the radicals may also alkylate and inactivate digestive vacuolar proteins,
including the proteases involved in Hb digestion [19, 20, 27]. Digestive vacuole FPs play an
important role in Hb degradation [33]. The activity of these enzymes increased after ozonide
treatment (Fig 4B), and cysteine protease inhibition with E64d resulted in accumulation of
full-length Hb and digestive vacuole swelling, whereas these features were not seen in peroxide
treated-parasites (S6 Fig). These findings suggest that the digestive vacuole FPs are unlikely to
be the Hb proteases initially inactivated by the ozonides, and this may be important therapeuti-
cally as functional FPs are essential for peroxide antimalarial activity [28, 30, 52, 59]. Indeed,
ozonides (and artemisinins) are reported to alkylate a range of proteins localised to the parasite
digestive vacuole, including other proteases involved in Hb digestion, for example, plasmep-
sins [19, 20, 27], which could be the initial intraparasitic protein targets important for peroxide
antimalarial activity. Consistent with our hypothesis that disrupted Hb catabolism is the key
early event initiated by peroxide treatment, we demonstrated that the initial antiparasitic
effects of peroxide exposure were enhanced when parasites were forced to rely solely on Hb
degradation for amino acids (Fig 4E). Taken together, we propose that Hb digestion is the ini-
tial pathway affected as a result of peroxide antimalarial treatment, however, the precise molec-
ular mechanism responsible for altered Hb catabolism remains unclear.
Depletion of short Hb-derived peptides following peroxide treatment was also confirmed
in artemisinin resistant (Cam3.IIR539T) and sensitive (Cam3.IIrev) parasite lines (Fig 2D) that
exhibit differential sensitivity to ozonides and DHA in the in vitro ring-stage survival assay
[30, 31, 60]. It should be noted that there are conflicting reports on the activity of ozonides
against parasite strains with reduced artemisinin sensitivity in the in vitro ring-stage survival
assay and this appears to be dependent on the ozonide and K13 mutation tested [60–62]. We
found that the level of drug-induced peptide depletion was generally less extensive in the K13-
mutant (Cam3.IIR539T) compared to that in the drug-treated K13-wildtype revertant strain
(Cam3.IIrev) (Fig 2D), suggesting that both ozonides and DHA have diminished impact on Hb
catabolism in resistant parasites, supporting the hypothesis that in vitro cross-resistance exists
between artemisinins and ozonides in parasites with a R539T mutation. The diminished drug
effect on Hb catabolism may be a result of increased survival of K13-mutants following short
peroxide exposure and could be mediated by altered Hb metabolism [37, 63, 64], augmented
antioxidant defence pathways [37, 65, 66] or an enhanced stress response [32].
One caveat is that the precise origin of the depleted di, tri and tetrapeptides detected by
untargeted metabolomic screening cannot be definitively determined due to their short
sequences. MS/MS confirmation of the amino acid sequence was obtained for a subset of these
depleted peptides and the confirmed sequences could be mapped to Hb. Furthermore,
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combined with additional lines of evidence pointing to a mechanism involving ozonide-
induced disruption of Hb catabolism, it is likely that most of the small peptides that were per-
turbed by drug treatment originated from Hb. The short peptides unable to be mapped to Hb
could originate from other RBC proteins or Plasmodium proteins, and could be associated
with peroxide-induced inhibition of proteasome function and altered proteostasis [21]. It is
important to note that the majority of peptides detected in the metabolome were not perturbed
by drug treatment and most of these unaffected peptides could not be mapped to Hb. Further-
more, endogenous long peptides from only one Plasmodium protein were reproducibly per-
turbed by peroxide treatment. These data suggested that general parasite protein degradation
was not significantly affected as a result of these short peroxide exposures.
Extended drug treatment (> 3 h) induced disruption of additional biochemical pathways
beyond Hb catabolism, including lipid and nucleotide metabolism (Fig 6A), representing sec-
ondary biochemical pathways involved in peroxide activity. In both ring and trophozoite-stage
parasites, drug treatment induced an accumulation of several metabolic intermediates in the
de novo synthesis pathways of PC and PE lipids (known as the Kennedy Pathways) (Fig 6B and
S12 and S14 Figs), which are the major lipid components of parasite membranes [45]. Proteo-
mic analysis revealed that all enzymes directly upstream of the elevated metabolites in the Ken-
nedy Pathways were also increased in abundance (Fig 6B and S13 Fig), possibly to increase the
synthesis of PC and PE as a biochemical response to drug-induced membrane damage. These
findings are consistent with the biological activity of ozonides and artemisinins involving non-
specific damage to parasite membranes, such as the digestive vacuole and mitochondrial mem-
branes [67, 68], through lipid peroxidation, which becomes apparent after an extended dura-
tion of drug exposure (> 3 h) and the production of reactive oxygen species [67, 69–72].
Inhibiting the synthesis of key phospholipids is detrimental to parasite survival [73] and it is
likely that perturbation to this pathway contributes to peroxide antimalarial activity.
Prolonged ozonide and DHA exposure in trophozoite-stage parasites also led to the deple-
tion of DGs and TGs (Fig 6B and S12 Fig). These are the two main neutral glycerolipid species
in parasites [74] and these lipids increase in abundance as the asexual parasite matures, indi-
cating their importance for growth and development [74]. DGs and TGs are packaged into
neutral lipid bodies, which are closely associated with the parasite digestive vacuole [75–77].
Neutral lipid bodies are thought to concentrate free haem and catalyse its biocrystallisation
into non-toxic haemozoin [76–78], placing them proximal to the location where peroxide anti-
malarials are thought to be activated. Furthermore, fluorescently-tagged artemisinin and ozon-
ide derivatives have been shown to accumulate in neutral lipid bodies [70, 71]. Activated drug,
or potentially alkylated haem adducts [58], may therefore promote oxidative damage to DGs
and TGs within neutral lipid bodies and limit the availability of key neutral lipids that are
required for parasite development [74]. As DGs are key precursors for membrane phospho-
lipid synthesis (e.g. PC and PE), it is expected that DG depletion also contributes to the upre-
gulation of de novo phospholipid biosynthesis (Kennedy) pathways.
Disruption of the parasite pyrimidine biosynthetic pathway at both the metabolite and pro-
tein levels (Fig 6C and S15 and S16 Figs) was also apparent in ozonide and DHA treated para-
sites. This finding is consistent with previous studies demonstrating DHA-induced alterations
in parasite pyrimidine metabolism [45]. Furthermore, carbamoyl phosphate synthetase and
aspartate carbamoyl transferase, which catalyse the initial steps of parasite pyrimidine biosyn-
thesis, are reported to be alkylation targets of artemisinins, although this has not yet been
shown for the ozonides [19]. Peroxide-induced inhibition of one or both of these initial pyrim-
idine biosynthetic enzymes may be responsible for the depletion of downstream pyrimidine
biosynthesis intermediates, and a corresponding increase in the protein levels of some
enzymes in this pathway as a compensatory response, as shown in our study.
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The alternative hypothesis that these secondary pathways are non-specific responses in
dying parasites is also possible. However, different drug-specific biochemical responses were
reported in metabolomics, proteomics and peptidomics studies of other antimalarials, includ-
ing the 4-aminoquinolines that target the digestive vacuole via a different mechanism, and
even when parasites were exposed to drugs for extended durations [45–47, 79, 80]. Combined
with reports showing that peroxide antimalarials target proteins in both the phospholipid and
pyrimidine biosynthesis pathways [19, 20, 27] and colocalise with neutral lipids within iRBCs
[70, 71], the drug-specific biochemical responses of parasites detected in metabolomics studies
suggests that the secondary metabolic alterations observed here are likely ozonide-specific and
related to the pleiotropic effect of peroxides on parasite metabolism.
Our work demonstrating that peroxide antimalarials affect multiple aspects of parasite bio-
chemistry is consistent with previous reports [45, 46]. Global proteomic analysis of ozonide
and DHA-treated parasites revealed a pronounced enrichment of proteins involved in protein
translation and the ubiquitin-proteasome system (Fig 5 and S11 Fig). Previous studies have
shown that artemisinins inhibit protein translation and proteasome activity [21, 81], and the
observed enrichment in these pathways from our study may represent a response to this inhi-
bition, either by regulation of protein expression, or decreased degradation of these proteins.
Furthermore, the enrichment of proteins in the translation and proteasomal pathways may
reflect a general stress response to enhance protein turnover and mitigate peroxide-mediated
cellular damage [82]. Peroxide-induced oxidative insult and widespread protein alkylation is
thought to induce accumulation of damaged and misfolded proteins [22, 32, 83], and the para-
site relies on translational regulation and a functional ubiquitin-proteasome system to restore
proteostasis [84, 85].
Based on our findings, we have proposed a model for the MoA of peroxide antimalarials
(Fig 7). Hb-derived free haem activates the peroxide bond of ozonides (or artemisinins) within
the digestive vacuole and the resulting drug-derived radicals initially alkylate haem [58] and
damage proteases involved in Hb digestion leading to disruption of the Hb degradation path-
way. In a futile response to drug-induced damage, the parasite increases the levels of Hb-
digesting proteases to restore normal Hb catabolism. Following prolonged exposure, drug-
derived radicals induce further oxidative insult and cause widespread alkylation of parasite
components, including damage to lipids, and proteins involved in other vital parasite func-
tions. To mitigate drug-induced cellular damage, the parasite engages a proteostatic stress
response involving upregulation of proteins involved in translational regulation and the ubi-
quitin-proteasome system. Parasite death ultimately occurs when drug-mediated damage
overwhelms these parasite defensive mechanisms. In artemisinin resistance, K13 mutations
alter parasite Hb metabolism [37, 63, 64] and enhance antioxidant capacity [37, 65, 66] and
stress response pathways [32], limiting the damage of drug-derived radicals and increasing
parasite survival.
Although DHA had a more rapid and pronounced effect on metabolism compared to the
ozonides, these antimalarials affected similar biochemical pathways suggesting that they have a
similar MoA. This could raise concerns for the deployment of ozonides in areas affected by
artemisinin resistance [86], which is characterised by infections with parasites that can with-
stand the short DHA exposures observed in the pharmacokinetics of clinically-used artemisi-
nins [17, 30]. However, the temporal metabolomics analysis demonstrated that prolonged
peroxide exposure perturbed additional pathways beyond the digestive vacuole, raising the
possibility that long half-life ozonides (e.g. OZ439) may impact additional parasite functions
during prolonged exposure, and potentially overcome resistance associated with the short-
lived artemisinins. There are mixed reports regarding ozonide activity in artemisinin resistant
parasites, and further clinical studies are required to determine the potential utility of ozonides
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Fig 7. Proposed model for ozonide antimalarial activity in P. falciparum infected red blood cells. Haemoglobin-derived haem activates peroxide antimalarials within
the parasite digestive vacuole. The resulting drug-derived radicals initially damage components proximal to the activation site, including proteases involved in
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in artemisinin resistant malaria infections [58]. In the context of growing concerns about the
spread of multi-drug resistant malaria parasites, this insight into the MoA of peroxide antima-
larials, and the parasite’s response to treatment, offers potential avenues for targeting the
malaria parasite with novel drug regimens that have improved antimalarial efficacy and limit
the generation of drug resistance.
Materials and methods
Plasmodium falciparum culture conditions
P. falciparum parasites (3D7 strain, Cam3.IIR539T, and Cam3.IIrev) were cultured as previously
described [87]. RBCs were obtained from the Australian Red Cross Blood Service in Mel-
bourne. Artemisinin resistant and sensitive P. falciparum isolates were kindly provided by Pro-
fessor David Fidock, Columbia University and included the field-derived K13-mutant, Cam3.
IIR539T, and the K13-wildtype on an isogenic background (Cam3.IIrev) [31]. Parasites were
tightly synchronised by double treatment with sorbitol [88]. For 3D7 parasites, trophozoite or
ring stage parasite cultures were adjusted to 10% parasitaemia and 2% Hct. For experiments
using artemisinin resistant and sensitive isolates, trophozoite parasite cultures were adjusted to
4% parasiteamia and 2% Hct.
Metabolomics sample preparation
In 3D7 parasites, a comprehensive time-course analysis was performed to determine the per-
oxide-induced metabolic profile in ring- and trophozoite-stage parasites. Ring-stage parasite
cultures (6–12 h post invasion) were exposed to drug (1 μM of OZ277 or OZ439, 300 nM of
DHA and 0.03% DMSO) for 0, 3, 6 and 9 h prior to metabolite extraction, while trophozoite
stage parasite cultures (28–34 h post invasion) were exposed to drug (300 nM of OZ277 or
OZ439, 100 nM of DHA and< 0.03% DMSO) for 0, 0.5, 1.5, 3, 6 and 9 h.
In artemisinin resistant and sensitive isolates, prior to drug incubation, the age of paired
artemisinin sensitive and resistant parasites was confirmed by analysis of Giemsa stained thin
blood smears. Trophozoite parasite cultures (22–26 h) were exposed to 100 nM of DHA,
OZ277 and OZ439 nM for a duration of 1, 3 and 5 h, respectively. Under the conditions used
in this metabolomics study (4% parasitaemia and 2% Hct), these concentrations were found to
be sub-lethal in both the Cam3.IIR539T and Cam3.IIrev parasite lines (< 50% loss of viability for
DHA and OZ277 after a 1 h and 3 h pulse, respectively, and< 40% loss of viability for OZ439
after a 3 h pulse). Metabolomics studies included treatment of non-infected RBCs as controls
and all experiments were performed on at least three independent occasions.
Following drug incubation, for ring-stage experiments (3D7), metabolites were extracted
from 2 x 108 cells using 200 μL of cold chloroform/methanol/water (1:3:1), while for trophozo-
ite stage experiments (3D7), 1 x 108 cells were used and metabolites extracted using 150 μL of
cold chloroform/methanol/water (1:3:1). For trophozoite stage experiments (3D7) where long-
haemoglobin digestion (arrow shown in blue). This leads to disruption of the haemoglobin degradation pathway. To correct for peroxide-induced damage, parasites may
respond by increasing the levels of proteases involved in haemoglobin catabolism. Peroxide radicals induce further oxidative insult and cause widespread alkylation of
parasite components as the duration of drug exposure is increased (arrows shown in green). This may include damage to lipids, inducing upregulation of the Kennedy
Pathways, and proteins involved in other vital parasite functions, such as pyrimidine biosynthesis. To mitigate peroxide-induced cellular damage, the parasite engages a
stress response involving translational regulation and the ubiquitin-proteasome systems. Asp, aspartic acid; ATC, aspartate carbamoyltransferase; C-Asp, carbamoyl-
aspartate, C-Phos, carbamoyl-phosphate; CCT, choline-phosphate cytidyltransferase; CDP-, cytidine-diphospho-; CEPT, choline/ethanolamine phosphotransferase; Cho,
choline; CK, choline kinase; CMP, cytidine monophosphate; CPS, carbamoyl phosphate synthetase; DHO, dihydroorotate; DHODH, dihydroorotate dehydrogenase;
DHOtase, dihydroorotase; DV, digestive vacuole; ECT, ethanolamine-phosphate cytidyltransferase; EK, ethanolamine kinase; Etn, ethanolamine; Gln, glutamine; Hb,
haemoglobin; OMPDC, orotodine 5’-phosphate decarboxylase; OPRT, orotate phosphoribosyltransferase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PCho,
choline phosphate; PEtn, ethanolamine phosphate; PMT, phosphoethanolamine N-methyltransferase; RBC, red blood cell; UMP, uridine monophosphate.
https://doi.org/10.1371/journal.ppat.1008485.g007
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term peroxide treatment was used (up to 9 h), metabolites were extracted from 1 x 108 cells
using 150 μL of cold methanol. For artemisinin resistant and sensitive isolates, 1 x 108 cells
were used and metabolites extracted using 150 μL of cold methanol. Metabolomics extraction
was as previously described [46]. Insoluble precipitates were removed by centrifugation and
110 μL of metabolite extract was transferred to glass LC-MS vials and stored at -80˚C until
analysis. A 15 μL aliquot of each sample was combined to generate a pooled biological quality
control (PBQC) sample for analytical quality control and metabolite identification procedures.
Untargeted metabolomics LC-MS analysis and data processing
To measure the metabolic perturbations induced by peroxide antimalarials in iRBCs and infer
the major pathways affected by treatment we employed an untargeted approach. Untargeted
analyses profile all detectable metabolite signals within a biological system, can be employed
without existing knowledge of a putative drug target and are particularly useful when multiple
targets might be involved in drug action. In contrast, targeted metabolite analyses are hypothe-
sis-driven experiments that are more suited when the mode of action of an antimalarial is sus-
pected and measures drug-induced changes to a predefined subset of metabolites, often
restricted to a particular metabolic pathway [89].
Untargeted LC-MS analysis was performed using HILIC chromatography (ZIC-pHILIC;
Merck) with an alkaline mobile phase on an Ultimate U3000 LC system (Dionex) and Q Exac-
tive Orbitrap MS (ThermoFisher) operating in both positive and negative ion mode as previ-
ously described [37, 46]. The PBQC sample was run periodically throughout each LC-MS
batch to monitor signal reproducibility and support downstream metabolite identification.
Extraction solvent was used as blank samples to identify possible contaminating chemical spe-
cies. To aid in metabolite identification, approximately 250 authentic metabolite standards
were analysed prior to each LC-MS batch and their peaks and retention time manually
checked using the ToxID software (Thermofisher).
Metabolomics data were analysed using the IDEOM workflow [90]. High confidence
metabolite identification (MSI level 1) was made by matching accurate mass and retention
time to authentic metabolite standards [91]. Putative identifications (MSI level 2) for metabo-
lites lacking standards were based on exact mass and predicted retention times [92]. Specifi-
cally, the identification of peptides was based on either accurate mass or a combination of
accurate mass and MS/MS analysis, which allowed definitive confirmation of the amino acid
sequence in selected peptides. In the ring and artemisinin resistance studies, LC-MS peak
heights representing metabolite abundances were normalised by median peak height, while
quality control procedures indicated that normalisation of metabolite abundances was not
required in the 3D7 trophozoite studies. Univariate statistical analysis was performed using
IDEOM and Welch’s t test [90]. Multivariate statistical analysis was performed on the mean
centred and auto-scaled data using the web-based tools in Metaboanalyst [93]. Sparse partial
least squares–discriminant analysis (sPLS-DA) algorithms were run with increasing numbers
of metabolites in each component (up to 150 metabolites), with minor changes to the model
when more than 10 metabolites were used. The final sPLS-DA plots shown in the supplemen-
tary data were developed using 10 metabolites in each component. Significant metabolites (P-
value� 0.05) were confirmed by manual integration of raw LC-MS peak areas in TraceFinder
(ThermoFisher).
Functional assays to measure haemoglobin abundance
The Hb fractionation assay was adapted from [35, 80]. Briefly, 3D7 trophozoite-stage parasites
were incubated with DHA, OZ277, OZ439, E64d or a DMSO control for either 1 or 3 h.
PLOS PATHOGENS Multi-omics analysis of ozonide mode of action
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008485 June 26, 2020 19 / 32
Following incubation, Hb, haem and haemozoin species were separated and measured using
the Hb fractionation assay [35, 80], and smears were made using Giemsa stain to check for par-
asite viability and digestive vacuole morphology by light microscopy. For the Hb fractionation
assay, the samples were normalised via a paired analysis to the DMSO control and graphed as
their fold change vs DMSO ± SD. All fractions had >4 replicates from >2 independent
experiments.
Hb monomer was also measured using SDS-PAGE gel. Briefly, 3D7 trophozoite-stage parasites
were incubated with OZ277, E64d or a DMSO control for 3 h. Following incubation, extracted
parasites were resolved on SDS-PAGE gels and proteins stained using Coomassie blue.
Peptidomics sample preparation
Peptidomics samples were prepared as previously described with minor modifications [37].
Briefly, intracellular parasites were harvested after 3 h of drug treatment followed by trichloro-
acetic acid protein precipitation and centrifugal filtration using a 10 kDa cut-off filter (Amicon
Ultra). The flow-through containing endogenous peptides was collected and peptide concen-
tration was measured using a bicinchoninic acid (BCA) protein assay (Thermo Scientific
Pierce) as per manufacturer’s protocol. Equal concentration of peptides (53–75 μg) were used
for peptidomic analysis. Peptide samples were then subjected to desalting using in-house gen-
erated C18 StageTips [94]. The elutes were then dried and resuspended in 20 μL of 2% (v/v)
acetonitrile (ACN) and 0.1% (v/v) formic acid (FA) for LC-MS/MS analysis.
Peptidomics nanoLC-MS/MS analysis and data processing
LC-MS/MS analysis was performed using an Ultimate U3000 Nano LC system (Dionex) and
Q Exactive Orbitrap MS (ThermoFisher) as previously described [37].
Peptide identification was performed using PEAKS DB software [95]. Maximum mass devi-
ation and false discovery rates were set at 0.5 Da and 0.01 respectively. No post translational
modification or digestion were selected and identified peptide sequences were matched to
Homo sapiens and P. falciparum databases. The mass to charge ratio and retention time of
each identified peptide were imported into TraceFinder (ThermoFisher) and the peak inten-
sity for each peptide was obtained manually. Further statistical analyses (Student’s t test) were
performed using Microsoft Excel for paired drug treated and DMSO control samples.
Proteomics sample preparation and triplex stable isotope dimethyl labelling
Proteomics samples were prepared as previously described with minor modifications [37]. Briefly,
1000 μg of protein, accurately determined using Pierce BCA assay, from each sample was incu-
bated overnight with sequencing grade trypsin (Promega) (1:50) at 37˚C. Quantitative triplex sta-
ble isotope dimethyl labelling was initiated on the following day using light, intermediate or heavy
dimethyl labelling reagents [96]. The samples were then subjected to ion-exchange fractionation
using a disposable Strong Cationic Exchange Solid Phase Extraction cartridge (Agilent Bond Elut)
[97]. The fractions were desalted using in-house generated StageTips [94], dried and resuspended
in 20 μL of 2% (v/v) ACN and 0.1% (v/v) FA for LC-MS/MS analysis.
Proteomics nanoLC-MS/MS analysis and data processing
LC-MS/MS analysis was performed using an Ultimate U3000 Nano LC system (Dionex) and
Q Exactive Orbitrap MS (ThermoFisher) as previously described [37]. Protein identification
and quantification was performed using the MaxQuant proteomics software [98]. The data
analysis parameters in MaxQuant were set as previously described [37] with minor
PLOS PATHOGENS Multi-omics analysis of ozonide mode of action
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008485 June 26, 2020 20 / 32
modifications. Dimethylation settings were adjusted to triplets; DimetNterm0 with
DimetLys0, DimetNterm4 with DimetLys4 and DimetNterm8 with DimetLys8 were selected
as light, intermediate and heavy label respectively. To correct for differences in protein amount
between groups, the protein ratios were normalised in MaxQuant at the peptide level so that
the log2 ratio is zero [98]. Known contaminants such as trypsin, keratin and reverse sequences
were removed from the MaxQuant output. Fold-changes for the drug treated samples relative
to the DMSO control samples were calculated in Microsoft Excel. One sample t-test was used
to test the mean of combined experiment groups against the known mean (μ = 0) [99]. For
each drug, the proteins that were identified in at least three independent experiments were fil-
tered based on P-value (� 0.05) and fold-change (� 1.5) to generate a list of significantly per-
turbed proteins. The bioinformatics interaction network analysis tool STRINGdb [100] was
used to build a protein-protein interaction network using the significantly perturbed proteins.
Connectivity was based on experimental, database and co-expression evidence and a strict
minimum interaction score (> 0.7) was applied to limit false positive associations in the pre-
dicted network. The STRINGdb protein connectivity output was exported to Cytoscape 3.6
[101] and the ClusterONE algorithm was used to integrate and visualise relationships between
proteins that were significantly perturbed by drug treatment.
Temporal activity-based protein profiling of cysteine protease activity
using activity-based probes
Activity-based probes (ABPs) were used to measure protease activity [42] following ozonide
exposure according to established methods [102]. In these assays, tightly synchronised tropho-
zoite stage parasites (28–34 h post invasion, 10% parasitaemia and 2% Hct) were treated with
OZ277 (300 or 1000 nM) or OZ439 (300 nM) for up to 5 h. Untreated parasite controls con-
tained an equivalent volume of DMSO (< 0.01%). Following ozonide treatment, parasites were
purified by lysing the red blood cells using 0.1% saponin on ice. Parasite pellets were then lysed
by sonication in citrate buffer (50 mM trisodium citrate [pH 5.5], 0.5% CHAPS, 0.1% Triton X-
100, 4 mM dithiothreitol) or phosphate buffered saline (PBS) (pH 7.2). Supernatants were then
cleared by centrifugation and transferred to new tubes. Protein concentration in each sample
was determined using BCA protein assay (Pierce) and an equal amount of each sample was
incubated with ABPs (DCG04; 2 μM or FY01; 1 μM) for 30 min at 37˚C to label active cysteine
proteases. In experiments including the reversible cysteine protease inhibitor N-acetyl-Leu-Leu-
Norleu-al (ALLN) (Merck), parasite lysates were pre-incubated with 10 μM of the inhibitor for
30 min prior to addition of the ABP for a further 15 min. In all cases, the reaction was quenched
by the addition of 5x reducing buffer (50% glycerol, 250 mM Tris-Cl [pH 6.9], 10% SDS, 0.05%
bromophenol blue, 6.25% beta-mercaptoethanol), boiled and separated by sodium dodecyl sul-
fate polyacrylamide (SDS-PAGE) on 15% polyacrylamide gels. As DCG04 is biotin-tagged, pro-
teins were transferred to nitrocellulose membranes and incubated with streptavidin-AlexaFluor-
647 followed by fluorescence detection with a Cy5 filter (excitation/emission: 649/670 nm) with
an Amersham Typhoon 5 Biomolecular Imager (GE Healthcare Life Sciences). FY01 contains a
Cy5 fluorophore, thus visualization of its targets was achieved by direct scanning of the gel for
Cy5 fluorescence. Coomassie staining was used to confirm equal protein loading. Images were
processed and quantified in either ImageJ 1.51f or Adobe Photoshop Creative Cloud 2017.
Determination of antimalarial potency on parasites cultured in complete
RPMI medium or medium lacking exogenous amino acids (except isoleucine)
Full RPMI medium 1640 (Sigma-Aldrich) contained all 20 amino acids and was supplemented
with 5.94 g/l HEPES, 2.1 g/l NaHCO3, 50 mg/l hypoxanthine and 5 g/l Albumax II (Lifetech),
PLOS PATHOGENS Multi-omics analysis of ozonide mode of action
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008485 June 26, 2020 21 / 32
making AA medium. RPMI medium 1640 lacking all amino acids (Life Research) was supple-
mented with isoleucine (Sigma-Aldrich) at a final concentration of 147.5 μM to make Iso
medium [43]. All other supplements (HEPES, NaHCO3, hypoxanthine and Albumax II) were
added as for AA medium above. To examine parasite susceptibility to the peroxide antimalari-
als in the Iso and AA mediums, drug pulse activity assays were performed as previously
described [103]. Briefly, the medium of iRBC cultures containing 30 h trophozoite-stage para-
sites (10% parasitaemia and 2% Hct) was replaced with either Iso or AA medium immediately
before initiating drug treatment. Parasites were treated with 300 nM of pyrimethamine,
OZ277 or OZ439 or 100 nM of DHA for 3 h. Following the incubation period, drugs were
removed by washing the cultures as previously described [28] using either AA or Iso medium
supplemented with 2–5% Albumax II. Cultures were then adjusted to 0.5% parasitaemia and
2% Hct (final volume, 200 μL) as previously described [28] with either Iso or AA medium.
After 48 h the parasitaemia was measured by counting Giemsa stained thin blood smears. Par-
asite survival was determined by graphing the parasitaemia for each test compound relative to
the appropriate untreated medium (Iso or AA) control, which was set to 100%. All assays were
performed in triplicate in at least three independent experiments.
Supporting information
S1 Fig. Integrative multi-omics (metabolomics, peptidomics and proteomics) and activity-
based protein profiling (ABPP) workflows for the comprehensive analysis of peroxide
antimalarial action in P. falciparum infected red blood cells (RBCs). Metabolomics (green
boxes) samples were extracted from infected RBCs at regular intervals (up to 9 h after drug
addition) and the extracted samples were analysed by LC-MS and processed using IDEOM.
For peptidomics (blue boxes), endogenous peptides were extracted from saponin-lysed para-
sites, samples were subjected to 10 kDa cut-off centrifugal filtration and then an equal amount
of peptides were used for analysis by nanoLC-MS/MS before data was processed using PEAKS
software. Protein pellets following trichloracetic acid (TCA) precipitation were collected for
proteomic sample preparation (brown boxes). Equal amount of proteins were digested using
trypsin, labelled using dimethyl labelling to allow differential quantitative proteomic analysis
and examined using nanoLC-MS/MS followed by data processing using MaxQuant. ABPP
assays (red boxes) were performed by selectively labelling active cysteine proteases in the para-
site lysate using various activity-based probes (ABPs), then visualising protease activity in a
gel-based format.
(TIF)
S2 Fig. Metabolic perturbations in trophozoite stage parasite cultures. a, Percentage of sig-
nificantly perturbed metabolites (Welch’s t test; P-value < 0.05 and fold change� 1.5) follow-
ing exposure to increasing durations of OZ277 (blue), OZ439 (green) and DHA (red) (0.5, 1.5
and 3 h). b, Pathway enrichment analysis showing the percentage of significantly perturbed
metabolites (Welch’s t test; P-value < 0.05 and fold change > 1.5) as a function of metabolite
class for short (0.5, 1.5 and 3 h) exposure with OZ277, OZ439 (both 300 nM) and DHA (100
nM).
(TIF)
S3 Fig. Peroxide-induced metabolic perturbations in ring-stage parasite cultures. a, Per-
centage of significantly perturbed metabolites (Welch’s t test; P-value< 0.05 and fold-
change> 1.5) at each time point (0, 3, 6 and 9 h) following OZ277 (blue), OZ439 (green) and
DHA (red) treatment of ring-stage infected cultures. b, Heatmap showing the average fold
change for all identified peptides at each time point after OZ277, OZ439 and DHA treatment
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in ring-stage parasites. For each time point, values represent the average of four independent
biological replicates, expressed relative to the average untreated control value for that respec-
tive time point.
(TIF)
S4 Fig. Multivariate analysis of peroxide-induced perturbations in ring-stage parasite cul-
tures. a-c, Sparse partial least squares–discriminant analysis (sPLS-DA) of the metabolomics
data for ring-stage parasite infected RBCs treated with peroxide antimalarials for 3 h (a), 6 h
(b), and 9 h (c).
(TIF)
S5 Fig. Peroxide-induced alterations in peptide abundance in Cam3.IIrev and Cam3.IIR539T
parasite lines. a, Heatmap of differentially abundant peptides (altered� 1.5-fold relative to
the untreated control) in artemisinin-resistant Cam3.IIR539T and artemisinin-sensitive Cam3.
IIrev parasite lines following peroxide treatment. Data shown are the average for three or five
biological replicates expressed relative to the average for the untreated control from the sensi-
tive parasite line (DMSO, Cam3.IIrev).b, Sequence coverage for putative haemoglobin (Hb)-
derived peptides that were altered in abundance following peroxide antimalarial treatment
relative to the untreated control. All peptides, except TT and SK (or its isomers) were reduced
in abundance in treated parasites compared to control levels. The solid black bars represent
peptide sequences that were confirmed by MS/MS analysis and the dashed bars represent
putative peptide sequences. For putative peptide sequences, all potential isomers have been
mapped.
(TIF)
S6 Fig. Peroxide-induced alterations in haemoglobin abundance in 3D7 parasite lines. a, A
panel of representative giemsa stained parasites treated with 300 nM of OZ277 or OZ439, 100
nM of DHA, a DMSO negative control or a 27 μM E64d positive control for a swollen digestive
vacuole after 1 h and 3 h. b, Bar charts representing the relative levels of haemoglobin, free
heme and hemozoin in trophozoite-stage parasites following either a 1 or 3 h incubation with
300 nM of OZ277 and OZ439, 100 nM of DHA or 27 μM of E64d expressed as the fold change
when compared to a DMSO control. Bars represent the mean of>4 paired replicates from at
least two independent experiments with the error bars expressed as SD. c, SDS-PAGE gel
image of haemoglobin monomer band following treatment with OZ277 (300 nM for 3 h),
E64d (27 μM for 3 h) and DMSO control. d, Haemoglobin α and β abundance measured using
quantitative proteomics for treated parasites (100 nM DHA, 300 nM OZ277 and OZ439 for 3
h), values are the average fold change (± SD) relative to the untreated control of at least three
biological replicates.
(TIF)
S7 Fig. Volcano plot showing the global proteomic changes associated with peroxide anti-
malarial treatment of trophozoite-stage parasite cultures. Proteins identified in at least
three independent experiments following treatment of trophozoite stage parasites with OZ277
(1293 proteins, indicated by blue colour dots), OZ439 (1284 proteins, green dots) and DHA
(1613 proteins, red dots). Trophozoite infected cultures were incubated with OZ277, OZ439
(both 300 nM) or DHA (100 nM) for 3 h. Proteins above the significance threshold (P-
value� 0.05) and outside the grey shaded area (fold change� 1.5) were considered signifi-
cant.
(TIF)
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S8 Fig. Activity-based protein profiling of parasite cysteine protease activity after peroxide
treatment using the activity-based probe (ABP), DCG04 under neutral pH conditions. a,
Cysteine protease activity and densitometric analysis of the DPAP1 and FP 2/3 signal after
OZ277 and OZ439 treatment in P. falciparum trophozoite-stage parasites using DCG04 at pH
7.2 (neutral). Live parasites were treated for 1, 3 or 5 h with OZ277, OZ439 or DMSO (control)
in 3–4 independent experiments and the saponin lysates were labelled with DCG04 to deter-
mine cysteine protease activity. DCG04 labelling was detected by blotting membranes with
streptavidin-AF647 after SDS-PAGE and transfer. The lanes for each time point are indepen-
dent drug treatments and represent at least three biological replicates per time point that were
run on the same gel side-by-side. Densitometric analysis is shown relative to the untreated
control at the corresponding time point (±SD). b, ALLN inhibition of cysteine protease activity
under neutral (pH 7.2) and acidic (pH 5.5) conditions. Live parasites were treated for 3 h with
OZ277, OZ439 or DMSO (control) and the saponin lysates were pre-incubated with (+) or
without (-) the cysteine protease inhibitor ALLN (10 μM for 30 min) prior to labelling with
DCG04.
(TIF)
S9 Fig. Activity-based protein profiling of parasite cysteine protease activity after peroxide
treatment using the activity-based probe (ABP), FY01. a-b, SDS-PAGE gel showing parasite
cysteine protease activity after OZ277, OZ439 and DMSO (control) treatment in trophozoite-
stage parasites using the FY01 probe, at pH 5.5 (acidic) (a) and pH 7.2 (neutral) (b). Live para-
sites were treated for 1, 3 or 5 h in 3–4 independent experiments. Treated parasites were sapo-
nin lysed and labelled with FY01 to determine cysteine protease activity. Proteins were
resolved by SDS-PAGE and the gel was scanned for Cy5 fluorescence to detect probe labelling.
For (a) and (b) the lanes for each time point are independent drug treatments and represent at
least three biological replicates per time point that were run on the same gel side-by-side. <
Unidentified bands.
(TIF)
S10 Fig. P. falciparum parasite sensitivity to 48 h of OZ277 treatment when cultured in
complete (AA) and isoleucine alone (Iso) medium. Trophozoite-stage parasites at 1% parasi-
taemia and 2% haematocrit cultured in either medium containing all amino acids (AA, black
line) or isoleucine alone medium (Iso, grey line) were incubated with different concentration
of OZ277 for 48 h and the 50% inhibitory concentration (IC50) determined using the SYBR
green assay. The IC50 (nM) for OZ277 in parasites cultured in AA medium was 6.3 ± 1.6. The
IC50 (nM) for OZ277 in parasites cultured in Iso medium was 6.6 ± 1.1. IC50 results are the
mean and standard deviation of three biological repeats. A representative growth curve is
shown.
(TIF)
S11 Fig. Network analysis of parasite proteins perturbed following treatment with DHA.
The network analysis was built using the STRINGdb interaction network analysis output (con-
nectivity was based on experimental, database and co-expression evidence with a minimum
interaction score of 0.7) in Cytoscape 3.6 with the ClusterONE algorithm. Node size represents
P-value and node colour represents fold-change from at least three independent replicates.
(TIF)
S12 Fig. Peroxide-induced perturbations to lipid metabolism in trophozoite-stage parasite
cultures. a, Heatmap showing the average fold change for all identified lipids and lipid metab-
olites at each time point after prolonged exposure to OZ277, OZ439 and DHA in trophozoite-
stage P. falciparum parasites. Values represent the average of three biological replicates,
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expressed relative to the average untreated control value for that respective time point. b, De
novo synthesis pathways for phosphatidylcholine (PC) and phosphatidylethanolamine (PE) in
P. falciparum. Metabolites in red and blue were increased and decreased in abundance after
drug treatment respectively. Enzyme names are shown in solid boxes. The dashed arrow repre-
sents an alternative route for the synthesis of PC from ethanolamine (Etn) in P. falciparum. c,
Pathways for the synthesis of phospholipids and triglycerides from phosphatidic acid precur-
sors. CCT, choline-phosphate cytidyltransferase; CDP-, cytidine-diphospho-; CEPT, choline/
ethanolamine phosphotransferase; Cer, ceramide; Cho, choline; CK, choline kinase; CMP,
cytidine monophosphate; DAG/DG, diglyceride; DM-, dimethyl-; ECT, ethanolamine-phos-
phate cyitidyltransferase; EK, ethanolamine kinase; Etn, ethanolamine; GA, gangliosides; MM-
, monomethyl; PA, phosphatidic acid, PC, phosphatidylcholine; PCho, choline phosphate; PE,
phosphatidylethanolamine; PEtn, ethanolamine phosphate; PG, phosphatidylglycerol; PI,
phosphatidylinositol; PMT, phosphoethanolamine N-methyltransferase; PK, polyketides; PR,
prenols; PS, phosphatidylserine; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylser-
ine synthase; SD, serine decarboxylase; SM, sphingomyelin; TG, triglyceride; TM-,trimethyl;
�not detected.
(TIF)
S13 Fig. Peroxide-induced disruption of protein abundance for enzymes involved in the
synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids within
P. falciparum parasites. Values are the average fold change (± SD) relative to the untreated
control of at least three biological replicates. Choline-phosphate cytidyltransferase (CCT) was
only identified in one OZ439 experiment, therefore the mean from one experiment is shown.
The last step in both the PC and PE branches of the Kennedy Pathways are catalysed by the
enzyme choline/ethanolamine phosphotransferase (CEPT). For ease of representation, the
abundance of CEPT is only shown for the PC branch of the pathway. � p-value< 0.05. CCT,
choline-phosphate cytidyltransferase; CDP-, cytidine-diphospho-; CEPT, choline/ethanol-
amine phosphotransferase; Cer, ceramide; Cho, choline; CK, choline kinase; CMP, cytidine
monophosphate; DAG/DG, diglyceride; DM-, dimethyl-; ECT, ethanolamine-phosphate cyiti-
dyltransferase; EK, ethanolamine kinase; Etn, ethanolamine; GA, gangliosides; MM-, mono-
methyl; PA, phosphatidic acid, PC, phosphatidylcholine; PCho, choline phosphate; PE,
phosphatidylethanolamine; PEtn, ethanolamine phosphate; PG, phosphatidylglycerol; PI,
phosphatidylinositol; PMT, phosphoethanolamine N-methyltransferase; PK, polyketides; PR,
prenols; PS, phosphatidylserine; PSD, phosphatidylserine decarboxylase; PSS, phosphatidylser-
ine synthase; SD, serine decarboxylase; SM, sphingomyelin; TG, triglyceride; TM-,trimethyl.
(TIF)
S14 Fig. Time-dependent peroxide-induced perturbations of metabolites in the phosphatidyl-
choline (PC) and phosphatidylethanolamine de novo synthesis pathways in ring infected cul-
tures. The abundances of each of the metabolites after treatment with OZ277 (blue), OZ439
(green) and DHA (red) are the average fold change (± SD) relative to the untreated control of
four biological replicates. Metabolites in red were increased in abundance after drug treatment.
Enzyme names are shown in solid boxes. The dashed arrow represents an alternative route for the
synthesis of PC from ethanolamine (Etn) in P. falciparum parasites. CCT, choline-phosphate cyti-
dyltransferase; CDP-, cytidine-diphospho-; CEPT, choline/ethanolamine phosphotransferase;
Cho, choline; CK, choline kinase; CMP, cytidine monophosphate; ECT, ethanolamine-phosphate
cytidyltransferase; EK, ethanolamine kinase; Etn, ethanolamine; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PCho, choline phosphate; PEtn, ethanolamine phosphate; PMT, phos-
phoethanolamine N-methyltransferase; �not detected.
(TIF)
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S15 Fig. Peroxide-induced perturbation of metabolites in the pyrimidine biosynthesis
pathway in trophozoite-stage parasite cultures. Values are the average fold change (± SD)
relative to the untreated control of three biological replicates. For the pyrimidine biosynthesis
pathway, blue circles represent metabolites that are decreased in abundance, yellow circles rep-
resent no change and black circles represent metabolites that were not detected. Hb, haemo-
globin; UMP, uridine monophosphate.
(TIF)
S16 Fig. Peroxide-induced disruption of protein abundance for enzymes involved in the P.
falciparum pyrimidine biosynthesis pathway. Values are the average fold change (± SD) rela-
tive to the untreated control of at least three biological replicates. Orotate phosphoribosyltrans-
ferase was not detected in OZ277 treated parasites and was only identified in one OZ439
experiment. � p-value < 0.05.
(TIF)
S1 Dataset. IDEOM metabolomics output for OZ277, OZ439 and DHA treatment of P. fal-
ciparum (3D7 strain) ring and trophozoite infected RBC cultures and uninfected RBC cul-
tures.
(XLSX)
S2 Dataset. IDEOM metabolomics output for OZ277, OZ439 and DHA treatment of
Cam3.IIR539T (artemisinin resistant) and Cam3.IIrev (artemisinin sensitive) P. falciparum
parasite lines.
(XLSX)
S3 Dataset. Peptidomics dataset for OZ277, OZ439 and DHA treatment (3 h) of P. falcipa-
rum trophozoite infected RBC cultures (3D7 strain).
(XLSX)
S4 Dataset. Peptidomics dataset for DHA treatment (1 h) of P. falciparum trophozoite
infected RBC cultures (Cam3.IIrev, artemisinin sensitive).
(XLSX)
S5 Dataset. Proteomics dataset for OZ277, OZ439 and DHA treatment of P. falciparum
trophozoite infected RBC cultures (3D7 strain).
(XLSX)
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